The Morgan Welch Inflammatory Breast Cancer Research Program is committed to finding what causes inflammatory breast cancer and identifying new treatment options. We are conducting a number of treatment-based studies and a wide variety of lab-based studies to understand this disease better. The list below highlights the ongoing trials being run by the IBC research program and clinic. Additional IBC clinical trials can be found at ClinicalTrials.gov.
Protocol 2006-1072: Inflammatory Breast Cancer (IBC) Registry
The goal of this research study is to collect blood and tissue samples, and clinical data from patients with a diagnosis of inflammatory breast cancer who either have never received treatment (Cohort 1) or have previously received treatment (Cohort 2) for IBC. Samples and information collected from patients with IBC are very precious and critical for the researchers to learn about the disease and to find the cure for the disease. The samples will be banked at MD Anderson Cancer Center and will be used for future critical IBC research that have been or will be approved by the MDACC Institutional Review Board. Patients’ information and privacy are protected and maintained at all times.
Protocol 2016-0177: A randomized phase II study of carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen for newly diagnosed primary triple negative breast cancer
Protocol 2016-0538: A phase Ib study of neratinib, pertuzumab, trastuzumab with taxol (3HT) in primary metastatic and locally advanced breast cancer, and phase II study of 3HT followed by AC in HER2+ primary IBC and neratinib with taxol (NT) followed by AC in HR+, HER2- primary IBC (phase 2 part only)
Protocol 2018-0002: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer
Protocol 2016-0096: A phase II study of anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflammatory breast cancer (IBC) who did not achieve a pathological complete response (pCR) to neoadjuvant chemotherapy.
Protocol 2018-0550: Atorvastatin in triple-negative breast cancer (TNBC) patients who did not achieve a pathologic complete response (pCR) after receiving neoadjuvant chemotherapy
Protocol 2014-0533: A phase II study of anti-PD-1 (MK-3475) therapy in patients with metastatic inflammatory breast cancer (IBC) or non-IBC triple negative breast cancer (TNBC) who have achieved clinical response or stable disease to prior chemotherapy.
Protocol 2016-0890: A phase II study of triple combination of Atezolizumab, cobimetinib and eribulin (ACE) or Atezolizumab + eribulin (AE) in patients with recurrent/metastatic inflammatory breast cancer. [ACE cohort is no longer enrolling. AE is enrolling]
Protocol 2016-1096: A phase I study of OTS167PO, a MELK inhibitor, to evaluate safety, tolerability, and pharmacokinetics in patients with advanced breast cancer and dose-expansion study in patients with triple negative breast cancer
Protocol 2018-0493: A phase 1b/2 study of Rebastinib (DCC-2036) in combination with paclitaxel in patients with advanced or metastatic solid tumors (IBC cohort)